Urothelial Cancer Genomic Sequencing Study

Following the development of the first all-inclusive genomics test approved by the New York State Department of Health, the Englander Institute for Precision Medicine has made genetic sequencing widely available for cancer patients at NewYork-Presbyterian Hospital/Weill Cornell Medicine.

The objective of this research study is to assess the clinical importance of germline mutations in urothelial cancer (UC) by building a comprehensive registry of patients with the disease.

Patient Referrals

If you are a patient interested in precision medicine, please speak with your clinician or contact or submit inquiries and contact information to ipminfo@med.cornell.edu

Questions? Contact:

Weill Cornell Medicine’s Division of Hematology & Medical Oncology Clinic

Phone: 646-962-2072


Bishoy Morris Faltas, M.D.
Clinical Profile 

Research Profile